64th ASH Annual Meeting and Exposition: Classification Clarification: Consensus and Compromise

Special-Interest Sessions

clinical trials, Research, Clinical Practice (Health Services and Quality), Clinical Research, Diseases, Therapies, registries, Lymphoid Malignancies, Myeloid Malignancies, Technology and Procedures, Pathology

393-396 (Ernest N. Morial Convention Center)

Co-chairs:

Amy E. DeZern, MD, Johns Hopkins University and Margaret Kasner, MD, Jefferson University Hospital

Disclosures:

DeZern: GERON: Other: DSMB; Novartis: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; CTI BioPharma: Consultancy, Honoraria; Syntrix Pharmaceuticals: Research Funding. Kasner: Kartos/Telios: Research Funding; Ono: Research Funding; Otsuka: Research Funding; Gilead: Research Funding; Pfizer: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Kronos Bio: Other: Data and Safety Monitoring Board.

Confused about classifications? Looking for clarification? Join our hematopathology colleagues and hematologic malignancy experts as well as an FDA representative for a review and discussion of the new World Health Organization (WHO), International Consensus Classification (ICC), and European Leukemia Net (ELN) systems for diagnosis and management of lymphoid and myeloid disorders. There are modifications from previous, unresolved inconsistencies between existing systems, and new entities which could have profound impact on pathological reporting, clinical decision-making, clinical trial eligibility, drug labels, and disease registry reporting. The speakers will share practical paradigms and discuss steps to a future of consensus and compromise.

Changes to Myeloid Disease Classification

Rena R. Xian, MD, MS

Johns Hopkins Genomics, Johns Hopkins University School of Medicine, Baltimore, MD

Changes to Lymphoid Disease Classification

Lisa M. Rimsza, MD

Division of Hematopathology, Mayo Clinic - Scottsdale, Scottsdale, AZ

Perspective on Clinical Trial Issues

Andrew D. Zelenetz, MD, PhD

Memorial Sloan Kettering Cancer Center, New York, NY

FDA Perspective on Challenges Posed by Inconsistent Classifications

Kelly J. Norsworthy, MD

Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Severna Park, MD; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

See more of: Special-Interest Sessions

<< Previous Session | Next Session >>